Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.39 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3892401 | 0.97 | SRC (0.41) | SRCEGFRERBB2FDPSPTGER4 | |
| SCHEMBL3882532 | 0.85 | SRC (0.40) | SRCALDH1A1MAPTHPGDPTGER4 | |
| SCHEMBL3883366 | 0.83 | SRC (0.41) | SRCEGFRERBB2ALDH1A1 | |
| SCHEMBL3880394 | 0.83 | SRC (0.41) | SRCEGFRERBB2ABL1FLT1 | |
| SCHEMBL3891428 | 0.81 | SRC (0.38) | SRC | |
| SCHEMBL3889166 | 0.81 | SRC (0.38) | SRCALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL13955654 | 0.80 | KMT2A (0.46) | ALDH1A1MAPTHPGDMEN1POLB | |
| SCHEMBL14452724 | 0.80 | SRC (0.44) | SRCEGFRERBB2ABL1FLT1 | |
| SCHEMBL3879940 | 0.80 | EGFR (0.34) | SRCEGFRERBB2ABL1FLT1 | |
| SCHEMBL3879099 | 0.79 | SRC (0.43) | SRCEGFRERBB2ABL1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1771443-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006002828-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | SRC 1014/4885EGFR 1881/4885ERBB2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.